ADHD: ICD-11 criteria and differences from the DSM-5-TR — what has changed and how this impacts adult diagnosis Medically reviewed by PChina Jin LI (李锦) Institute of toxicology, Academy of Military Medical Sciences, Beijing ADHD definition and classification in ICD-11 In ICD-11, Attention-deficit/hyperactivity disorder (ADHD) is classified within the group of neurodevelopmental disorders, reflecting the…

Generic Atomoxetine Prices: What Changed in 2025? An in‑depth look at the ninth generic entrant and the latest price drop 1. Price timeline 2021 – 2025 MilestoneEventMarket effect May 2021Six‑month exclusivity for first‑to‑file (Teva) ends; three additional ANDAs launch.AWP for 40 mg/30‑count falls ≈ 8 % in Red Book snapshots. 2022Supply stabilises; insurers move generics to Tier 1.GoodRx cash price for 40 mg slides below $25.…

Strattera Price & Savings Guide 2025 Brand: $450 - $750 | Generic: $200 - $400 Discover the most current pricing information and savings options for Strattera (atomoxetine) in 2025 Check Current Discounts Strattera at a Glance Available Dosages Strattera comes in several capsule strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg Most common starting dose:…

Strattera vs Adderall: Cost, Onset and Side-Effects Over two decades after their respective U.S. launches Strattera (atomoxetine, 2002) and Adderall (mixed amphetamine salts, re-branded 1996) remain the archetypal representatives of non-stimulant and stimulant therapy for attention-deficit/hyperactivity disorder (ADHD). Both are endorsed by major guidelines including the 2023 American Academy of Pediatrics update and the 2025…

ADHD Comorbidities: Anxiety, Depression, Autism Spectrum Disorder Impact on Pharmacotherapy Selection and Clinical Outcomes By the Editorial Board of Shanghai Archives of Psychiatry Introduction: The Complexity of Comorbid ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) manifests with comorbid conditions in >75% of adults and >60% of children, with anxiety disorders (25-50%), depressive disorders (20-30%), and autism spectrum disorder…

Non-Stimulant Strategies in ADHD: Atomoxetine and Guanfacine in Modern Practice Abstract Despite stimulants remaining first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), approximately 30% of patients exhibit inadequate response or intolerable adverse effects 4, 8. This comprehensive review synthesizes current evidence on non-stimulant alternatives—atomoxetine and guanfacine—focusing on their neurobiological mechanisms, clinical efficacy across developmental stages, practical prescribing…

Does Insurance Cover Strattera? 2025 Update Why Strattera Coverage Varies Across Plans Strattera® (atomoxetine) faces inconsistent insurance coverage due to three key factors: Formulary Tier Placement: Most plans place brand-name Strattera on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), while generic atomoxetine typically sits on Tier 2 (preferred generic) :cite[1]:cite[3]. ADHD Medication Policies:…

ICD-11 vs DSM-5-TR: How Physicians Diagnose ADHD Today Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most researched neurodevelopmental conditions, yet the two major diagnostic manuals the World Health Organization’s ICD-11 and the American Psychiatric Association’s DSM-5-TR approach its criteria in subtly different ways. Understanding these differences is essential for evidence-based diagnosis and for tailoring pharmacotherapy, including…

Atomoxetine vs Guanfacine: Non-Stimulant Options in ADHD Not every person with attention-deficit/hyperactivity disorder (ADHD) can or should use stimulants. Some experience intolerable appetite loss or insomnia, others carry cardiovascular contraindications, and many parents simply want a Schedule-free option that will not be flagged at the pharmacy counter. 2024–2025 also witnessed recurrent shortages of both mixed…

Switching from Stimulants to Strattera: Step-by-Step Psychostimulants—methylphenidate, lisdexamfetamine, mixed amphetamine salts—remain the pharmacologic gold standard for attention-deficit/hyperactivity disorder (ADHD). Yet millions eventually need or want to stop them: appetite vanishes, insomnia mounts, telehealth refill rules tighten, or a cardiologist flags elevated QTc. When that moment arrives, the long-acting norepinephrine-reuptake inhibitor atomoxetine (brand name Strattera) is…